Patient, disease, and transplant characteristics
| . | T-cell depleted . | Non-T-cell depleted . | P . |
|---|---|---|---|
| N | 870 | 998 | |
| Median age, y (range) | 24 (0.4-57) | 28 (0.5-61) | .0001 |
| Performance score 90%, n/n eval (%) | 706/869 (81%) | 735/988 (74%) | .0001 |
| Disease and disease state, n/n eval (%) | .001 | ||
| ALL, 1st remission | 45/851 (5%) | 64/987 (6%) | |
| ALL, 2nd remission | 162/851 (19%) | 141/987 (14%) | |
| ALL, not in remission | 86/851 (10%) | 62/987 (6%) | |
| AML, 1st remission | 53/851 (6%) | 90/987 (9%) | |
| AML, 2nd remission | 51/851 (6%) | 66/987 (7%) | |
| AML, not in remission | 101/851 (12%) | 107/987 (11%) | |
| CML, 1st chronic phase | 203/851 (24%) | 292/987 (30%) | |
| CML, accelerated phase | 110/851 (13%) | 115/987 (12%) | |
| CML, blast phase | 40/851 (5%) | 50/987 (5%) | |
| Year of transplantation, n/n eval (%) | .0001 | ||
| 1982-1987 | 316/870 (36%) | 133/998 (14%) | |
| 1988-1994 | 554/870 (63%) | 865/998 (86%) | |
| Median interval diagnosis-transplant, mo (range) | |||
| ALL, 1st remission | 6 (2-21) | 7 (2-19) | NS |
| ALL, 2nd remission | 28 (5-148) | 34 (4-151) | NS |
| ALL, not in remission | 18 (3-73) | 13 (3-97) | NS |
| AML, 1st remission | 6 (2-17) | 6 (2-19) | NS |
| AML, 2nd remission | 21 (7-67) | 17 (5-88) | NS |
| AML, not in remission | 10 (3-54) | 10 (1-61) | NS |
| CML, 1st chronic phase | 20 (2-124) | 19 (2-123) | NS |
| CML, accelerated phase | 26 (2-107) | 27 (2-126) | NS |
| CML, blast phase | 27 (6-123) | 20 (2-116) | NS |
| Median WBC at diagnosis, ×109/L (range) | |||
| Acute leukemia | 16 (0.5-850) | 16 (0.4-882) | NS |
| Chronic leukemia | 164 (4-880) | 158 (4-760) | NS |
| Median donor age, y (range) | 35 (1-81) | 35 (1-75) | NS |
| Donor recipient sex-match, n/n eval (%) | NS | ||
| Male-male | 283/859 (33%) | 292/987 (30%) | |
| Male-female | 173/859 (20%) | 215/987 (22%) | |
| Female-male | 242/859 (28%) | 282/987 (28%) | |
| Female-female | 161/859 (19%) | 198/987 (20%) | |
| Donor-recipient CMV status, n/n eval (%) | .0001 | ||
| Negative-negative | 289/726 (40%) | 265/912 (29%) | |
| Negative-positive | 151/726 (21%) | 197/912 (21%) | |
| Positive-negative | 116/726 (16%) | 152/912 (17%) | |
| Positive-positive | 170/726 (23%) | 298/912 (33%) | |
| Median cell dose, ×108/kg (range) | 1.1 (0.1-12) | 3 (0.3-25) | .0001 |
| Conditioning regimen*, n/n eval (%) | .0001 | ||
| High intensity | 664/863 (77%) | 339/986 (34%) | |
| Standard intensity | 83/863 (10%) | 374/986 (38%) | |
| Busulfan + cyclophosphamide | 25/863 (3%) | 213/986 (22%) | |
| Other | 91/863 (10%) | 60/986 (6%) | |
| Donor-recipient relationship and HLA-match, n/n eval (%) | .0001 | ||
| Phenotypically matched related donor | 56/870 (6%) | 96/998 (10%) | |
| 1-Antigen mismatched related donor | 180/870 (21%) | 332/998 (33%) | |
| 2-Antigen mismatched related donor | 153/870 (18%) | 78/998 (8%) | |
| 3-Antigen mismatched related donor | 98/870 (11%) | 12/998 (1%) | |
| Phenotypically matched unrelated donor | 267/870 (31%) | 408/998 (41%) | |
| Mismatched unrelated donor | 116/870 (13%) | 72/998 (7%) | |
| Prophylactic use of growth factors†, n/n eval (%) | 79/870 (9) | 103/998 (10) | NS |
| Posttransplant immune suppression, n/n eval (%) | — | ||
| Methotrexate (MTX) | 39/869 (4%) | ||
| Cyclosporine A (CsA) | 399/869 (46%) | ||
| CsA + MTX | 40/869 (5%) | 998/998 (100%) | |
| CSA + Corticosteroids | 120/869 (14%) | ||
| Corticosteroids | 91/869 (10%) | ||
| Other | 25/869 (3%) | ||
| None | 155/869 (18%) |
| . | T-cell depleted . | Non-T-cell depleted . | P . |
|---|---|---|---|
| N | 870 | 998 | |
| Median age, y (range) | 24 (0.4-57) | 28 (0.5-61) | .0001 |
| Performance score 90%, n/n eval (%) | 706/869 (81%) | 735/988 (74%) | .0001 |
| Disease and disease state, n/n eval (%) | .001 | ||
| ALL, 1st remission | 45/851 (5%) | 64/987 (6%) | |
| ALL, 2nd remission | 162/851 (19%) | 141/987 (14%) | |
| ALL, not in remission | 86/851 (10%) | 62/987 (6%) | |
| AML, 1st remission | 53/851 (6%) | 90/987 (9%) | |
| AML, 2nd remission | 51/851 (6%) | 66/987 (7%) | |
| AML, not in remission | 101/851 (12%) | 107/987 (11%) | |
| CML, 1st chronic phase | 203/851 (24%) | 292/987 (30%) | |
| CML, accelerated phase | 110/851 (13%) | 115/987 (12%) | |
| CML, blast phase | 40/851 (5%) | 50/987 (5%) | |
| Year of transplantation, n/n eval (%) | .0001 | ||
| 1982-1987 | 316/870 (36%) | 133/998 (14%) | |
| 1988-1994 | 554/870 (63%) | 865/998 (86%) | |
| Median interval diagnosis-transplant, mo (range) | |||
| ALL, 1st remission | 6 (2-21) | 7 (2-19) | NS |
| ALL, 2nd remission | 28 (5-148) | 34 (4-151) | NS |
| ALL, not in remission | 18 (3-73) | 13 (3-97) | NS |
| AML, 1st remission | 6 (2-17) | 6 (2-19) | NS |
| AML, 2nd remission | 21 (7-67) | 17 (5-88) | NS |
| AML, not in remission | 10 (3-54) | 10 (1-61) | NS |
| CML, 1st chronic phase | 20 (2-124) | 19 (2-123) | NS |
| CML, accelerated phase | 26 (2-107) | 27 (2-126) | NS |
| CML, blast phase | 27 (6-123) | 20 (2-116) | NS |
| Median WBC at diagnosis, ×109/L (range) | |||
| Acute leukemia | 16 (0.5-850) | 16 (0.4-882) | NS |
| Chronic leukemia | 164 (4-880) | 158 (4-760) | NS |
| Median donor age, y (range) | 35 (1-81) | 35 (1-75) | NS |
| Donor recipient sex-match, n/n eval (%) | NS | ||
| Male-male | 283/859 (33%) | 292/987 (30%) | |
| Male-female | 173/859 (20%) | 215/987 (22%) | |
| Female-male | 242/859 (28%) | 282/987 (28%) | |
| Female-female | 161/859 (19%) | 198/987 (20%) | |
| Donor-recipient CMV status, n/n eval (%) | .0001 | ||
| Negative-negative | 289/726 (40%) | 265/912 (29%) | |
| Negative-positive | 151/726 (21%) | 197/912 (21%) | |
| Positive-negative | 116/726 (16%) | 152/912 (17%) | |
| Positive-positive | 170/726 (23%) | 298/912 (33%) | |
| Median cell dose, ×108/kg (range) | 1.1 (0.1-12) | 3 (0.3-25) | .0001 |
| Conditioning regimen*, n/n eval (%) | .0001 | ||
| High intensity | 664/863 (77%) | 339/986 (34%) | |
| Standard intensity | 83/863 (10%) | 374/986 (38%) | |
| Busulfan + cyclophosphamide | 25/863 (3%) | 213/986 (22%) | |
| Other | 91/863 (10%) | 60/986 (6%) | |
| Donor-recipient relationship and HLA-match, n/n eval (%) | .0001 | ||
| Phenotypically matched related donor | 56/870 (6%) | 96/998 (10%) | |
| 1-Antigen mismatched related donor | 180/870 (21%) | 332/998 (33%) | |
| 2-Antigen mismatched related donor | 153/870 (18%) | 78/998 (8%) | |
| 3-Antigen mismatched related donor | 98/870 (11%) | 12/998 (1%) | |
| Phenotypically matched unrelated donor | 267/870 (31%) | 408/998 (41%) | |
| Mismatched unrelated donor | 116/870 (13%) | 72/998 (7%) | |
| Prophylactic use of growth factors†, n/n eval (%) | 79/870 (9) | 103/998 (10) | NS |
| Posttransplant immune suppression, n/n eval (%) | — | ||
| Methotrexate (MTX) | 39/869 (4%) | ||
| Cyclosporine A (CsA) | 399/869 (46%) | ||
| CsA + MTX | 40/869 (5%) | 998/998 (100%) | |
| CSA + Corticosteroids | 120/869 (14%) | ||
| Corticosteroids | 91/869 (10%) | ||
| Other | 25/869 (3%) | ||
| None | 155/869 (18%) |